Modulating the antitumor immunity of MBT-2 murine bladder tumor bearing mice by postoperative administration of interferon-α

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This study was conducted mainly to investigate the effect of interferon-α (IFN-α) on the antitumor immunity of a tumor bearing host (TBH) when postoperatively administrated with or without lethally irradiated autologous tumor cells. Using the C3H/He-MBT-2 murine bladder tumor model, a status of postoperative residual tumor was mimicked by rechallenging tumor cells 24 hours after resecting the day-17 tumor. Using immunohistochemical analysis we demonstrated that after treating with lethally irradiated MBT-2 tumor cells (IRMBT-2) + IL-2 cells of CD4+, CD8+, CD44+ and CD11b+ phenotypes prominently infiltrate the subcutaneous local injection sites. In contrast only scanty immune responding cells could be seen locally if treated with IRMBT-2 + IFN-α2b, albeit in the presence of interleukin-2 (IL-2). However, the spleens of D17TBM treated with IRMBT-2 + IFN-α2b contained the highest percentage of CD44+ memory T cells and cells of the CD11b+ phenotype; moreover, their natural killer (NK), lymphokine activated killer (LAK) and cytotoxic T lymphocytes (CTL) activities were significantly augmented. The results of in vivo tumor rechallenge revealed that administration of IFN-α, either alone or combined with IRMBT-2, could both effectively suppress the outgrowth of perioperative rechallenged tumor cells as well as prolong the survival of TBH. We conclude that despite the presence of autologous tumor vaccine, postoperative administration of IFN-α can further enhance the antitumor immunity of TBH and therefore can be an effective adjuvant therapy to improve the therapeutic results of surgery on a tumor bearing host.

Original languageEnglish
Pages (from-to)3355-3361
Number of pages7
JournalAnticancer Research
Volume18
Issue number5 A
Publication statusPublished - 1998 Sep

Fingerprint

Urinary Bladder Neoplasms
Interferons
Immunity
Neoplasms
Interleukin-2
Phenotype
Cancer Vaccines
Lymphokines
Residual Neoplasm
Cytotoxic T-Lymphocytes
Subcutaneous Injections
Spleen
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

@article{5644fa001f234363bd8ad6074a558502,
title = "Modulating the antitumor immunity of MBT-2 murine bladder tumor bearing mice by postoperative administration of interferon-α",
abstract = "This study was conducted mainly to investigate the effect of interferon-α (IFN-α) on the antitumor immunity of a tumor bearing host (TBH) when postoperatively administrated with or without lethally irradiated autologous tumor cells. Using the C3H/He-MBT-2 murine bladder tumor model, a status of postoperative residual tumor was mimicked by rechallenging tumor cells 24 hours after resecting the day-17 tumor. Using immunohistochemical analysis we demonstrated that after treating with lethally irradiated MBT-2 tumor cells (IRMBT-2) + IL-2 cells of CD4+, CD8+, CD44+ and CD11b+ phenotypes prominently infiltrate the subcutaneous local injection sites. In contrast only scanty immune responding cells could be seen locally if treated with IRMBT-2 + IFN-α2b, albeit in the presence of interleukin-2 (IL-2). However, the spleens of D17TBM treated with IRMBT-2 + IFN-α2b contained the highest percentage of CD44+ memory T cells and cells of the CD11b+ phenotype; moreover, their natural killer (NK), lymphokine activated killer (LAK) and cytotoxic T lymphocytes (CTL) activities were significantly augmented. The results of in vivo tumor rechallenge revealed that administration of IFN-α, either alone or combined with IRMBT-2, could both effectively suppress the outgrowth of perioperative rechallenged tumor cells as well as prolong the survival of TBH. We conclude that despite the presence of autologous tumor vaccine, postoperative administration of IFN-α can further enhance the antitumor immunity of TBH and therefore can be an effective adjuvant therapy to improve the therapeutic results of surgery on a tumor bearing host.",
author = "Tzai, {Tzong Shin} and Ai-Li Shiau and Chao-Liang Wu and Nan-Haw Chow and Yuh-Shyan Tsai",
year = "1998",
month = "9",
language = "English",
volume = "18",
pages = "3355--3361",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 A",

}

TY - JOUR

T1 - Modulating the antitumor immunity of MBT-2 murine bladder tumor bearing mice by postoperative administration of interferon-α

AU - Tzai, Tzong Shin

AU - Shiau, Ai-Li

AU - Wu, Chao-Liang

AU - Chow, Nan-Haw

AU - Tsai, Yuh-Shyan

PY - 1998/9

Y1 - 1998/9

N2 - This study was conducted mainly to investigate the effect of interferon-α (IFN-α) on the antitumor immunity of a tumor bearing host (TBH) when postoperatively administrated with or without lethally irradiated autologous tumor cells. Using the C3H/He-MBT-2 murine bladder tumor model, a status of postoperative residual tumor was mimicked by rechallenging tumor cells 24 hours after resecting the day-17 tumor. Using immunohistochemical analysis we demonstrated that after treating with lethally irradiated MBT-2 tumor cells (IRMBT-2) + IL-2 cells of CD4+, CD8+, CD44+ and CD11b+ phenotypes prominently infiltrate the subcutaneous local injection sites. In contrast only scanty immune responding cells could be seen locally if treated with IRMBT-2 + IFN-α2b, albeit in the presence of interleukin-2 (IL-2). However, the spleens of D17TBM treated with IRMBT-2 + IFN-α2b contained the highest percentage of CD44+ memory T cells and cells of the CD11b+ phenotype; moreover, their natural killer (NK), lymphokine activated killer (LAK) and cytotoxic T lymphocytes (CTL) activities were significantly augmented. The results of in vivo tumor rechallenge revealed that administration of IFN-α, either alone or combined with IRMBT-2, could both effectively suppress the outgrowth of perioperative rechallenged tumor cells as well as prolong the survival of TBH. We conclude that despite the presence of autologous tumor vaccine, postoperative administration of IFN-α can further enhance the antitumor immunity of TBH and therefore can be an effective adjuvant therapy to improve the therapeutic results of surgery on a tumor bearing host.

AB - This study was conducted mainly to investigate the effect of interferon-α (IFN-α) on the antitumor immunity of a tumor bearing host (TBH) when postoperatively administrated with or without lethally irradiated autologous tumor cells. Using the C3H/He-MBT-2 murine bladder tumor model, a status of postoperative residual tumor was mimicked by rechallenging tumor cells 24 hours after resecting the day-17 tumor. Using immunohistochemical analysis we demonstrated that after treating with lethally irradiated MBT-2 tumor cells (IRMBT-2) + IL-2 cells of CD4+, CD8+, CD44+ and CD11b+ phenotypes prominently infiltrate the subcutaneous local injection sites. In contrast only scanty immune responding cells could be seen locally if treated with IRMBT-2 + IFN-α2b, albeit in the presence of interleukin-2 (IL-2). However, the spleens of D17TBM treated with IRMBT-2 + IFN-α2b contained the highest percentage of CD44+ memory T cells and cells of the CD11b+ phenotype; moreover, their natural killer (NK), lymphokine activated killer (LAK) and cytotoxic T lymphocytes (CTL) activities were significantly augmented. The results of in vivo tumor rechallenge revealed that administration of IFN-α, either alone or combined with IRMBT-2, could both effectively suppress the outgrowth of perioperative rechallenged tumor cells as well as prolong the survival of TBH. We conclude that despite the presence of autologous tumor vaccine, postoperative administration of IFN-α can further enhance the antitumor immunity of TBH and therefore can be an effective adjuvant therapy to improve the therapeutic results of surgery on a tumor bearing host.

UR - http://www.scopus.com/inward/record.url?scp=0031761902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031761902&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 3355

EP - 3361

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 A

ER -